Search Results

You are looking at 281 - 290 of 384 items for :

  • "Neutropenia" x
  • Refine by Access: All x
Clear All
Full access

Evaluation of Scores to Reflect Toxicity Impact on Quality of Life of Patients With Platinum-Resistant Ovarian Cancer: AURELIA Substudy

Justine Lequesne, Florence Joly, Julien Peron, Isabelle Ray-Coquard, Anne-Claire Hardy-Bessard, Frédéric Selle, Dominique Berton, Philippe Follana, Michel Fabbro, Alain Lortholary, Eric Pujade-Lauraine, Sophie Lefèvre-Arbogast, and Elodie Coquan

, respectively, whereas 113 (31.4%) experienced maximal-grade 2 AEs and 33 (9.2%) did not experience any grade ≥2 AEs. The most frequently observed AEs were fatigue (30.3%), neutropenia (28.6%), anemia (23.9%), abdominal pain (20%), and hypertension (15

Full access

First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort

Esther N. Pijnappel, Willemieke P.M. Dijksterhuis, Lydia G. van der Geest, Judith de Vos-Geelen, Jan Willem B. de Groot, Marjolein Y.V. Homs, Geert-jan Creemers, Nadia Haj Mohammad, Marc G. Besselink, Hanneke W.M. van Laarhoven, Johanna W. Wilmink, and for the Dutch Pancreatic Cancer Group

of grade 3/4 toxicities (eg, neutropenia, thrombocytopenia, fatigue, vomiting). 13 , 27 , 28 Because the OS of patients receiving FOLFIRINOX in our study was higher among both those with PS 0–1 and those with PS 2 compared with those receiving

Full access

Frailty in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Receiving Curative-Intent Therapy: A Population-Based Study

Abi Vijenthira, Lee Mozessohn, Chenthila Nagamuthu, Ning Liu, Danielle Blunt, Shabbir Alibhai, Anca Prica, and Matthew C. Cheung

spent a significantly longer number of days in the hospital compared with nonfrail patients. During both time frames, the top 3 reasons for admission among both frail and nonfrail patients were fever/infection/neutropenia, lymphoma, and symptom

Full access

How to Choose Frontline Therapy for Chronic Myelogenous Leukemia: So Many Drugs, Not So Many Patients

Paul J. Shami

. Thrombocytopenia was more common with dasatinib, whereas neutropenia occurred at equal frequency. Edema, nausea, vomiting, and rashes were more common with imatinib. In earlier studies, pleural effusions were seen in patients treated with dasatinib, particularly at

Full access

Counterpoint: Adjuvant Therapy in Stage II Colon Cancer: Pain Not Justified by the Gain

Katherine Van Loon and Alan P. Venook

the MOSAIC trial, 0.5% of patients in each arm died during treatment and as many as 40% of patients experienced grade 3 or 4 neutropenia. 7 Moreover, although the addition of oxaliplatin possibly provides an absolute survival benefit of 1.5% compared

Full access

New Agents in Metastatic Prostate Cancer

Atish D. Choudhury and Philip W. Kantoff

was accompanied by increased toxicity compared with mitoxantrone, with higher rates of grade 3 or greater neutropenia (82% vs. 58%), neutropenic fever (8% vs. 1%), and diarrhea (6% vs. <1%), along with greater requirements for dose reductions (12% vs

Full access

Hematopoietic Progenitor Cell Transplantation in Children, Adolescents, and Young Adults With Relapsed Mature B-Cell NHL

Aliza Gardenswartz and Mitchell S. Cairo

-front in newly diagnosed DLBCL in combination with chemotherapy. 34 PV is generally well tolerated. The most common grade 3–4 events reported in the single-agent study by Palanca-Wessels et al 31 were neutropenia, anemia, and peripheral sensory neuropathy

Full access

Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab

Ganessan Kichenadasse, John O. Miners, Arduino A. Mangoni, Andrew Rowland, Ashley M. Hopkins, and Michael J. Sorich

not consider anemia (36 episodes), thrombocytopenia (7 episodes), neutropenia (5 episodes), and lymphopenia (3 episodes) to be irAEs. Table 2. Baseline Clinical Characteristics and Outcomes of Atezolizumab-Treated Patients Table 3. Baseline Laboratory

Full access

Epidemiology, Natural History, and Practice Patterns of Patients with Myelodysplastic Syndromes in 2010

Mikkael A. Sekeres

had significant cytopenias: 82% had anemia, 46% thrombocytopenia, and 45% neutropenia. Furthermore, 65% previously received a blood transfusion, 52% of which had been given within the prior 3 months; 64% had been receiving blood transfusions for 1 year

Full access

NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018

Gregory P. Kalemkerian, Billy W. Loo Jr, Wallace Akerley, Albert Attia, Michael Bassetti, Yanis Boumber, Roy Decker, M. Chris Dobelbower, Afshin Dowlati, Robert J. Downey, Charles Florsheim, Apar Kishor P. Ganti, John C. Grecula, Matthew A. Gubens, Christine L. Hann, James A. Hayman, Rebecca Suk Heist, Marianna Koczywas, Robert E. Merritt, Nisha Mohindra, Julian Molina, Cesar A. Moran, Daniel Morgensztern, Saraswati Pokharel, David C. Portnoy, Deborah Rhodes, Chad Rusthoven, Jacob Sands, Rafael Santana-Davila, Charles C. Williams Jr, Karin G. Hoffmann, and Miranda Hughes

, 1.18; 95% CI, 0.95–1.45; P =.14). Although toxicity was generally similar between the arms, patients receiving 45 Gy of accelerated RT had more grade 4 neutropenia than those receiving 66 Gy of conventional RT (49% [129/266] vs 38% [101/263]; P